AU764068B2 - Amelioration of apomorphine adverse effects - Google Patents
Amelioration of apomorphine adverse effects Download PDFInfo
- Publication number
- AU764068B2 AU764068B2 AU49651/99A AU4965199A AU764068B2 AU 764068 B2 AU764068 B2 AU 764068B2 AU 49651/99 A AU49651/99 A AU 49651/99A AU 4965199 A AU4965199 A AU 4965199A AU 764068 B2 AU764068 B2 AU 764068B2
- Authority
- AU
- Australia
- Prior art keywords
- apomorphine
- dose
- patient
- administering
- sublingual
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 229960004046 apomorphine Drugs 0.000 title claims description 155
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 title claims description 153
- 230000000694 effects Effects 0.000 title claims description 60
- 230000002411 adverse Effects 0.000 title claims description 37
- 238000000034 method Methods 0.000 claims description 34
- 239000003814 drug Substances 0.000 claims description 24
- 238000011287 therapeutic dose Methods 0.000 claims description 24
- 230000001965 increasing effect Effects 0.000 claims description 18
- 230000036470 plasma concentration Effects 0.000 claims description 16
- 230000001568 sexual effect Effects 0.000 claims description 14
- 208000024891 symptom Diseases 0.000 claims description 10
- 208000027089 Parkinsonian disease Diseases 0.000 claims description 8
- 206010034010 Parkinsonism Diseases 0.000 claims description 8
- 230000037396 body weight Effects 0.000 claims description 8
- 230000035515 penetration Effects 0.000 claims description 8
- 206010041250 Social phobia Diseases 0.000 claims description 5
- 239000002552 dosage form Substances 0.000 claims description 5
- 230000000638 stimulation Effects 0.000 claims description 4
- 230000000737 periodic effect Effects 0.000 claims description 3
- 238000010254 subcutaneous injection Methods 0.000 claims description 3
- 239000007929 subcutaneous injection Substances 0.000 claims description 3
- 201000001880 Sexual dysfunction Diseases 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 231100000872 sexual dysfunction Toxicity 0.000 claims description 2
- 230000018052 penile erection Effects 0.000 claims 2
- 239000000829 suppository Substances 0.000 claims 1
- 239000003826 tablet Substances 0.000 description 91
- 238000011282 treatment Methods 0.000 description 55
- 239000000902 placebo Substances 0.000 description 54
- 229940068196 placebo Drugs 0.000 description 54
- 206010047700 Vomiting Diseases 0.000 description 33
- 230000008673 vomiting Effects 0.000 description 28
- 241000282472 Canis lupus familiaris Species 0.000 description 26
- 229940079593 drug Drugs 0.000 description 23
- 230000001225 therapeutic effect Effects 0.000 description 20
- 206010028813 Nausea Diseases 0.000 description 18
- 201000001881 impotence Diseases 0.000 description 18
- 230000008693 nausea Effects 0.000 description 18
- 206010038776 Retching Diseases 0.000 description 16
- 238000007920 subcutaneous administration Methods 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- 230000007935 neutral effect Effects 0.000 description 12
- 206010052005 Psychogenic erectile dysfunction Diseases 0.000 description 10
- 230000004044 response Effects 0.000 description 9
- 208000010228 Erectile Dysfunction Diseases 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- 238000005259 measurement Methods 0.000 description 8
- 230000001107 psychogenic effect Effects 0.000 description 8
- 230000036772 blood pressure Effects 0.000 description 7
- 241000282412 Homo Species 0.000 description 6
- 208000018737 Parkinson disease Diseases 0.000 description 6
- 241001282135 Poromitra oscitans Species 0.000 description 6
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 6
- 206010048232 Yawning Diseases 0.000 description 6
- 230000001856 erectile effect Effects 0.000 description 6
- 230000006872 improvement Effects 0.000 description 6
- 230000035936 sexual power Effects 0.000 description 6
- 230000000007 visual effect Effects 0.000 description 6
- 206010060933 Adverse event Diseases 0.000 description 5
- 208000008454 Hyperhidrosis Diseases 0.000 description 5
- 208000001953 Hypotension Diseases 0.000 description 4
- 230000003474 anti-emetic effect Effects 0.000 description 4
- 239000002111 antiemetic agent Substances 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 4
- 230000007717 exclusion Effects 0.000 description 4
- 230000036543 hypotension Effects 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 230000036299 sexual function Effects 0.000 description 4
- 239000006190 sub-lingual tablet Substances 0.000 description 4
- 230000035900 sweating Effects 0.000 description 4
- 208000007848 Alcoholism Diseases 0.000 description 3
- 102000015554 Dopamine receptor Human genes 0.000 description 3
- 108050004812 Dopamine receptor Proteins 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- CXWQXGNFZLHLHQ-DPFCLETOSA-N apomorphine hydrochloride Chemical compound [H+].[H+].O.[Cl-].[Cl-].C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3.C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 CXWQXGNFZLHLHQ-DPFCLETOSA-N 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229940052760 dopamine agonists Drugs 0.000 description 3
- 230000002526 effect on cardiovascular system Effects 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 238000002483 medication Methods 0.000 description 3
- 210000001259 mesencephalon Anatomy 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 229940098466 sublingual tablet Drugs 0.000 description 3
- 229960003604 testosterone Drugs 0.000 description 3
- 238000002562 urinalysis Methods 0.000 description 3
- SKYZYDSNJIOXRL-BTQNPOSSSA-N (6ar)-6-methyl-5,6,6a,7-tetrahydro-4h-dibenzo[de,g]quinoline-10,11-diol;hydrochloride Chemical compound Cl.C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 SKYZYDSNJIOXRL-BTQNPOSSSA-N 0.000 description 2
- 208000020446 Cardiac disease Diseases 0.000 description 2
- 206010013654 Drug abuse Diseases 0.000 description 2
- 208000017701 Endocrine disease Diseases 0.000 description 2
- 206010057671 Female sexual dysfunction Diseases 0.000 description 2
- RPTUSVTUFVMDQK-UHFFFAOYSA-N Hidralazin Chemical compound C1=CC=C2C(NN)=NN=CC2=C1 RPTUSVTUFVMDQK-UHFFFAOYSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 206010058359 Hypogonadism Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 206010033546 Pallor Diseases 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 102000003946 Prolactin Human genes 0.000 description 2
- 108010057464 Prolactin Proteins 0.000 description 2
- 206010039897 Sedation Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 206010001584 alcohol abuse Diseases 0.000 description 2
- 208000025746 alcohol use disease Diseases 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 229960003990 apomorphine hydrochloride Drugs 0.000 description 2
- 230000037007 arousal Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 108091008690 chemoreceptors Proteins 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 230000003291 dopaminomimetic effect Effects 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 208000030172 endocrine system disease Diseases 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 230000000423 heterosexual effect Effects 0.000 description 2
- 208000031424 hyperprolactinemia Diseases 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 231100000518 lethal Toxicity 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 230000000422 nocturnal effect Effects 0.000 description 2
- 229940097325 prolactin Drugs 0.000 description 2
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000000284 resting effect Effects 0.000 description 2
- 201000000980 schizophrenia Diseases 0.000 description 2
- 230000036280 sedation Effects 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000011117 substance-related disease Diseases 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000024883 vasodilation Effects 0.000 description 2
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- YKFCISHFRZHKHY-NGQGLHOPSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)-2-methylpropanoic acid;trihydrate Chemical compound O.O.O.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1 YKFCISHFRZHKHY-NGQGLHOPSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- NFLLKCVHYJRNRH-UHFFFAOYSA-N 8-chloro-1,3-dimethyl-7H-purine-2,6-dione 2-(diphenylmethyl)oxy-N,N-dimethylethanamine Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC(Cl)=N2.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 NFLLKCVHYJRNRH-UHFFFAOYSA-N 0.000 description 1
- 208000026872 Addison Disease Diseases 0.000 description 1
- 206010002329 Aneurysm Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 208000019505 Deglutition disease Diseases 0.000 description 1
- 229940098778 Dopamine receptor agonist Drugs 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- 208000005819 Dystonia Musculorum Deformans Diseases 0.000 description 1
- 208000004547 Hallucinations Diseases 0.000 description 1
- 208000031361 Hiccup Diseases 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 208000002364 Leriche syndrome Diseases 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 206010027603 Migraine headaches Diseases 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- DMULVCHRPCFFGV-UHFFFAOYSA-N N,N-dimethyltryptamine Chemical compound C1=CC=C2C(CCN(C)C)=CNC2=C1 DMULVCHRPCFFGV-UHFFFAOYSA-N 0.000 description 1
- RTHCYVBBDHJXIQ-UHFFFAOYSA-N N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine Chemical compound C=1C=CC=CC=1C(CCNC)OC1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-UHFFFAOYSA-N 0.000 description 1
- 206010028817 Nausea and vomiting symptoms Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010031127 Orthostatic hypotension Diseases 0.000 description 1
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 1
- 101800000989 Oxytocin Proteins 0.000 description 1
- 102100031951 Oxytocin-neurophysin 1 Human genes 0.000 description 1
- RMUCZJUITONUFY-UHFFFAOYSA-N Phenelzine Chemical compound NNCCC1=CC=CC=C1 RMUCZJUITONUFY-UHFFFAOYSA-N 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 239000000150 Sympathomimetic Substances 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- BKPRVQDIOGQWTG-ICOOEGOYSA-N [(1s,2r)-2-phenylcyclopropyl]azanium;[(1r,2s)-2-phenylcyclopropyl]azanium;sulfate Chemical compound [O-]S([O-])(=O)=O.[NH3+][C@H]1C[C@@H]1C1=CC=CC=C1.[NH3+][C@@H]1C[C@H]1C1=CC=CC=C1 BKPRVQDIOGQWTG-ICOOEGOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- XSDQTOBWRPYKKA-UHFFFAOYSA-N amiloride Chemical compound NC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N XSDQTOBWRPYKKA-UHFFFAOYSA-N 0.000 description 1
- 229960002576 amiloride Drugs 0.000 description 1
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 230000000049 anti-anxiety effect Effects 0.000 description 1
- 230000001062 anti-nausea Effects 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940082992 antihypertensives mao inhibitors Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 229960002274 atenolol Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 238000004159 blood analysis Methods 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 230000036471 bradycardia Effects 0.000 description 1
- 208000006218 bradycardia Diseases 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
- 229960000830 captopril Drugs 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 229940083181 centrally acting adntiadrenergic agent methyldopa Drugs 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 1
- 229960001076 chlorpromazine Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 1
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 1
- 229960004170 clozapine Drugs 0.000 description 1
- 229940124301 concurrent medication Drugs 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 208000013219 diaphoresis Diseases 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 229960004042 diazoxide Drugs 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 208000016570 early-onset generalized limb-onset dystonia Diseases 0.000 description 1
- 229940011681 elavil Drugs 0.000 description 1
- 230000003028 elevating effect Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000002895 emetic Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 229960003883 furosemide Drugs 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 229960002474 hydralazine Drugs 0.000 description 1
- 229960002003 hydrochlorothiazide Drugs 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000001767 medulla oblongata Anatomy 0.000 description 1
- NZWOPGCLSHLLPA-UHFFFAOYSA-N methacholine Chemical compound C[N+](C)(C)CC(C)OC(C)=O NZWOPGCLSHLLPA-UHFFFAOYSA-N 0.000 description 1
- 229960002329 methacholine Drugs 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 239000002899 monoamine oxidase inhibitor Substances 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 229940087524 nardil Drugs 0.000 description 1
- -1 nausea Chemical compound 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000001272 neurogenic effect Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229960001597 nifedipine Drugs 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- XULSCZPZVQIMFM-IPZQJPLYSA-N odevixibat Chemical compound C12=CC(SC)=C(OCC(=O)N[C@@H](C(=O)N[C@@H](CC)C(O)=O)C=3C=CC(O)=CC=3)C=C2S(=O)(=O)NC(CCCC)(CCCC)CN1C1=CC=CC=C1 XULSCZPZVQIMFM-IPZQJPLYSA-N 0.000 description 1
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 1
- 229960001723 oxytocin Drugs 0.000 description 1
- 239000000734 parasympathomimetic agent Substances 0.000 description 1
- 210000003899 penis Anatomy 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 230000032361 posttranscriptional gene silencing Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- 229940035613 prozac Drugs 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 230000003997 social interaction Effects 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 229940127230 sympathomimetic drug Drugs 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 201000001340 torsion dystonia 1 Diseases 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 210000001186 vagus nerve Anatomy 0.000 description 1
- 229940072690 valium Drugs 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Gynecology & Obstetrics (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/138982 | 1998-08-24 | ||
| US09/138,982 US5994363A (en) | 1998-08-24 | 1998-08-24 | Amelioration of apomorphine adverse effects |
| PCT/US1999/014965 WO2000010567A1 (en) | 1998-08-24 | 1999-07-01 | Amelioration of apomorphine adverse effects |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU4965199A AU4965199A (en) | 2000-03-14 |
| AU764068B2 true AU764068B2 (en) | 2003-08-07 |
Family
ID=22484576
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU49651/99A Ceased AU764068B2 (en) | 1998-08-24 | 1999-07-01 | Amelioration of apomorphine adverse effects |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US5994363A (enExample) |
| EP (1) | EP1105129A4 (enExample) |
| JP (1) | JP2002523370A (enExample) |
| CN (1) | CN1212841C (enExample) |
| AU (1) | AU764068B2 (enExample) |
| BR (1) | BR9913235A (enExample) |
| CA (1) | CA2341673A1 (enExample) |
| CZ (1) | CZ2001610A3 (enExample) |
| HU (1) | HUP0201212A3 (enExample) |
| IL (1) | IL141512A0 (enExample) |
| NO (1) | NO20010899L (enExample) |
| NZ (1) | NZ510359A (enExample) |
| PL (1) | PL346273A1 (enExample) |
| WO (1) | WO2000010567A1 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050065161A1 (en) * | 1996-02-02 | 2005-03-24 | Nitromed, Inc. | Nitrosated and nitrosylated alpha-adrenergic receptor antagonist compounds, compositions and their uses |
| US6472425B1 (en) | 1997-10-31 | 2002-10-29 | Nitromed, Inc. | Methods for treating female sexual dysfunctions |
| BR0005797A (pt) * | 2000-03-20 | 2001-10-16 | Abbott Lab | Métodos para o tratamento de disfunção sexual com apomorfina em nìveis de concentração plasmática especificados |
| SK15772002A3 (sk) | 2000-04-07 | 2003-09-11 | Tap Pharmaceutical Products Inc. | Deriváty apomorfínu, ich použitie a farmaceutická kompozícia s ich obsahom |
| CA2408399A1 (en) * | 2000-05-09 | 2001-11-15 | Nitromed, Inc. | Infrared thermography and methods of use |
| DE10053397A1 (de) | 2000-10-20 | 2002-05-02 | Schering Ag | Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen |
| DE10043321B4 (de) * | 2000-08-24 | 2005-07-28 | Neurobiotec Gmbh | Verwendung eines transdermalen therapeutischen Systems zur Behandlung der Parkinsonschen Krankheit, zur Behandlung und Prävention des prämenstruellen Syndroms und zur Lactationshemmung |
| KR20030074810A (ko) * | 2001-02-08 | 2003-09-19 | 파마시아 코포레이션 | 성 기능장애의 치료를 위한 신속-발현 약 |
| ES2180446B1 (es) * | 2001-07-02 | 2004-01-16 | Esteve Labor Dr | Empleo de derivados de acidos 2,5-dihidroxibencenosulfonicos en la elaboracion de un medicamento para potenciar el efecto de otros farmacos en el tratamiento de la disfuncion erectil. |
| CN100346832C (zh) * | 2002-02-07 | 2007-11-07 | 法玛西雅公司 | 经粘膜递送的药物剂型 |
| WO2003080074A1 (en) * | 2002-03-19 | 2003-10-02 | Michael Holick | Glycoside and orthoester glycoside derivatives of apomorphine, analogs, and uses thereof |
| SI2561860T1 (en) * | 2002-05-31 | 2018-05-31 | Titan Pharmaceuticals, Inc. | An implantable polymeric device for prolonged release of buprenorphine |
| AU2003284005B2 (en) * | 2002-10-03 | 2009-12-17 | Forest Laboratories Holdings Limited | Dosage escalation and divided daily dose of anti-depressants to treat neurological disorders |
| US20050031667A1 (en) * | 2003-03-31 | 2005-02-10 | Patel Rajesh A. | Implantable polymeric device for sustained release of dopamine agonist |
| US20040204439A1 (en) * | 2003-04-14 | 2004-10-14 | Staniforth John Nicholas | Composition, device, and method for treating sexual dysfunction via inhalation |
| US20060178394A1 (en) * | 2003-04-14 | 2006-08-10 | Staniforth John N | Pharmaceutical compositions comprising apomorphine for pulmonary inhalation |
| EP1737458A4 (en) * | 2004-04-13 | 2010-08-04 | Mclean Hospital Corp | R (-) - 11-HYDROXYPORPHINE DERIVATIVES AND THEIR USE |
| US20060083724A1 (en) * | 2004-10-01 | 2006-04-20 | Hilst Todd W | Compositions for the treatment of femal sexual dysfunction |
| US7994220B2 (en) | 2005-09-28 | 2011-08-09 | Cypress Bioscience, Inc. | Milnacipran for the long-term treatment of fibromyalgia syndrome |
| US20110111014A1 (en) * | 2007-06-26 | 2011-05-12 | Parkinson's Institute | Methods and compositions for treatment of neurological disorders |
| US8431591B2 (en) * | 2007-07-12 | 2013-04-30 | The Mclean Hospital Corporation | R(−)-2-methoxy-11-hydroxyaporphine and derivatives thereof |
| GB0721394D0 (en) * | 2007-10-31 | 2007-12-12 | Vectura Group Plc | Compositions for trating parkinson's disease |
| DK2952191T3 (en) | 2009-06-12 | 2018-12-10 | Sunovion Pharmaceuticals Inc | Sublingual apomorphine |
| CA3115378A1 (en) | 2010-12-16 | 2012-06-21 | Sunovion Pharmaceuticals Inc. | Sublingual films comprising apomorphine and an organic base |
| EP2545905A1 (en) * | 2011-07-11 | 2013-01-16 | Britannia Pharmaceuticals Limited | A new therapeutical composition containing apomorphine as active ingredient |
| JP7211706B2 (ja) | 2015-04-21 | 2023-01-24 | サノヴィオン ファーマシュティカルズ インコーポレーテッド | 口腔粘膜へのアポモルフィンの投与によるパーキンソン病の治療方法 |
| IT202100009857A1 (it) | 2021-04-19 | 2022-10-19 | Univ Degli Studi Di Torino | Formulazione a rilascio controllato e prolungato di apomorfina |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5770606A (en) * | 1994-04-22 | 1998-06-23 | Pentech Pharmaceuticals, Inc. | Dosage forms and method for ameliorating male erectile dysfunction |
| US5939094A (en) * | 1994-12-23 | 1999-08-17 | Pentech Pharamaceticals, Inc. | Transdermal administration of apomorphine |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2818855A (en) * | 1954-02-11 | 1958-01-07 | Anthony P Miller | Surgical device |
| US3976780A (en) * | 1968-07-29 | 1976-08-24 | Societe D'etudes Scientifiques Et Industrielles L'ile-De-France | Methods of protection against emesis in mammals by administration of a 3-alkoxy-thianaphthene-2-carboxamide |
| US4127118B1 (en) * | 1977-03-16 | 1995-12-19 | Alvaro Latorre | Method of effecting and enhancing an erection |
| US4543256A (en) * | 1982-03-17 | 1985-09-24 | Northeastern University | (-)-10,1L Methylenedioxy-N-N-propylnoraporphine and methods employing it for inhibiting the effects of epileptic seizures and for prevention and treatment of duodenal ulcers |
| AU1508183A (en) * | 1982-06-04 | 1983-12-08 | Beecham Group Plc | Benzamide and anilide derivatives of 8-azabicyclo-(3.2.1)- -octane |
| US4687773A (en) * | 1983-03-28 | 1987-08-18 | Mclean Hospital | (+)-N-N-propylnorapomorphine and selective limbic activity |
| US4521421A (en) * | 1983-09-26 | 1985-06-04 | Eli Lilly And Company | Treatment of sexual dysfunction |
| US4749700A (en) * | 1984-10-23 | 1988-06-07 | Nastech Pharmaceutical Co, Inc. | Novel methods of administering antihistamines, antinausea and antiemetic pharmaceutical agents and novel dosage forms containing same |
| US4624965A (en) * | 1984-11-15 | 1986-11-25 | Nastech Pharmaceutical Co., Inc. | Novel method of administering anti-nausea and anti-emetic pharmaceutical agents and novel dosage forms containing same |
| US4772459A (en) * | 1986-09-09 | 1988-09-20 | Erbamont, Inc. | Method for controlling emesis caused by chemotherapeutic agents and antiemetic agents useful therein |
| US4749686A (en) * | 1986-12-04 | 1988-06-07 | New York Medical College | Combinations of renal vasodilators and α1 -adrenergic or ganglionic blocking agents and methods for treating diseases |
| US4801587A (en) * | 1987-03-02 | 1989-01-31 | Gene Voss | Impotence ointment |
| US5102887A (en) * | 1989-02-17 | 1992-04-07 | Arch Development Corporation | Method for reducing emesis and nausea induced by the administration of an emesis causing agent |
| US5242391A (en) * | 1990-04-25 | 1993-09-07 | Alza Corporation | Urethral insert for treatment of erectile dysfunction |
| US5270323A (en) * | 1990-05-31 | 1993-12-14 | Pfizer Inc. | Method of treating impotence |
| US5166145A (en) * | 1990-09-10 | 1992-11-24 | Alza Corporation | Antiemetic therapy |
-
1998
- 1998-08-24 US US09/138,982 patent/US5994363A/en not_active Expired - Fee Related
-
1999
- 1999-07-01 AU AU49651/99A patent/AU764068B2/en not_active Ceased
- 1999-07-01 BR BR9913235-4A patent/BR9913235A/pt not_active IP Right Cessation
- 1999-07-01 CA CA002341673A patent/CA2341673A1/en not_active Abandoned
- 1999-07-01 WO PCT/US1999/014965 patent/WO2000010567A1/en not_active Ceased
- 1999-07-01 IL IL14151299A patent/IL141512A0/xx unknown
- 1999-07-01 PL PL99346273A patent/PL346273A1/xx not_active Application Discontinuation
- 1999-07-01 NZ NZ510359A patent/NZ510359A/xx unknown
- 1999-07-01 CZ CZ2001610A patent/CZ2001610A3/cs unknown
- 1999-07-01 HU HU0201212A patent/HUP0201212A3/hu unknown
- 1999-07-01 EP EP99933642A patent/EP1105129A4/en not_active Withdrawn
- 1999-07-01 JP JP2000565888A patent/JP2002523370A/ja active Pending
- 1999-07-01 CN CNB998125210A patent/CN1212841C/zh not_active Expired - Fee Related
-
2001
- 2001-02-22 NO NO20010899A patent/NO20010899L/no not_active Application Discontinuation
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5770606A (en) * | 1994-04-22 | 1998-06-23 | Pentech Pharmaceuticals, Inc. | Dosage forms and method for ameliorating male erectile dysfunction |
| US5939094A (en) * | 1994-12-23 | 1999-08-17 | Pentech Pharamaceticals, Inc. | Transdermal administration of apomorphine |
Also Published As
| Publication number | Publication date |
|---|---|
| NZ510359A (en) | 2003-06-30 |
| WO2000010567A1 (en) | 2000-03-02 |
| AU4965199A (en) | 2000-03-14 |
| NO20010899L (no) | 2001-04-24 |
| EP1105129A1 (en) | 2001-06-13 |
| HUP0201212A2 (en) | 2002-08-28 |
| CZ2001610A3 (cs) | 2002-03-13 |
| PL346273A1 (en) | 2002-01-28 |
| JP2002523370A (ja) | 2002-07-30 |
| BR9913235A (pt) | 2001-12-04 |
| CN1212841C (zh) | 2005-08-03 |
| CN1324238A (zh) | 2001-11-28 |
| NO20010899D0 (no) | 2001-02-22 |
| CA2341673A1 (en) | 2000-03-02 |
| US5994363A (en) | 1999-11-30 |
| IL141512A0 (en) | 2002-03-10 |
| HUP0201212A3 (en) | 2004-12-28 |
| EP1105129A4 (en) | 2003-11-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU764068B2 (en) | Amelioration of apomorphine adverse effects | |
| US6200983B1 (en) | Dosage forms containing apomorphine for ameliorating male erectile dysfunction | |
| US6306437B1 (en) | Apomorphine-containing dosage forms for ameliorating male erectile dysfunction | |
| JP5411504B2 (ja) | 薬物嗜癖および行動嗜癖を治療するためのイブジラストの使用 | |
| US6566368B2 (en) | Apomorphine-containing dosage form for ameliorating male erectile dysfunction | |
| US20070281924A1 (en) | MIF inhibitors for treating neuropathic pain and associated syndromes | |
| EP3454853B1 (en) | Treatment of alcoholism and depression using ibudilast | |
| MXPA01001877A (en) | Amelioration of apomorphine adverse effects | |
| WO1999064006A1 (en) | Use of a nk-1 receptor antagonist for treating psychiatric disorders | |
| HK1025742B (en) | Sublingual composition containing apomorphine for diagnosing functional impotence | |
| HK1014239B (en) | Sublingual dosage forms containing apomorphine for use in the treatment of erectile dysfunction |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |